A New Strategy of Cancer Immunotherapy Combining Hyperthermia/Oncolytic Virus Pretreatment with Specific Autologous Anti-Tumor Vaccination – A Review

@inproceedings{Volker2017ANS,
  title={A New Strategy of Cancer Immunotherapy Combining Hyperthermia/Oncolytic Virus Pretreatment with Specific Autologous Anti-Tumor Vaccination – A Review},
  author={Schirrmacher Volker},
  year={2017}
}
This review describes and explains a specific immunotherapy strategy that has been developed at the Immunological and Oncological Center Cologne in Germany. [] Key Method The second step consists of active-specific autologous anti-tumor vaccination. The vaccine, VOL-DC, consists of autologous Dendritic Cells (DCs) which are loaded with Viral Oncolysate (VOL) from the patient’s tumor cells.

Figures and Tables from this paper

Breaking Therapy Resistance: An Update on Oncolytic Newcastle Disease Virus for Improvements of Cancer Therapy

The review focusses on oncolytic Newcastle disease virus (NDV) as a biological agent with potential to break therapy resistance and presents future perspectives, including the concept of in situ vaccination and the combination of NDV or other on colytic viruses with checkpoint inhibitors.

Counteracting Immunosuppression in the Tumor Microenvironment by Oncolytic Newcastle Disease Virus and Cellular Immunotherapy

An apparent paradox exists between the evidence for spontaneous systemic T cell- mediated anti-tumor immune responses in cancer patients, observed particularly in their bone marrow, and local tumor

Oncolytic Virotherapy in Glioma Tumors

The literature is revisited to describe the main OVs proposed up to the present moment in order to destroy glioma cells in vitro and trigger tumor destruction in vivo and highlight the results obtained in various clinical trials, which are exploring the use of these agents as an alternative where other approaches provide limited hope.

Thermal immuno-nanomedicine in cancer

The role of the various thermal therapies and an update on attempts to combine these with immunotherapies in clinical trials are described and the preclinical development of various thermal immuno-nanomedicines, which are capable of combining thermal therapies with various immunotherapy strategies in a single therapeutic platform are provided.

From chemotherapy to biological therapy: A review of novel concepts to reduce the side effects of systemic cancer treatment (Review)

The present review focused on immunotherapy, with the aim of reducing side effects and increasing long-lasting efficacy in cancer therapy.

The Effect of Oncolytic Reovirus P-92 on Dendritic Cell Maturation and Generation of Tumor-Specific Lymphocytes in vitro

It is found that the differentiation of DCs in the presence of reovirus P-92 increased the yield of mature DCs, and the antigen can be proposed as an effective experimental product for the cellular cancer immunotherapy.

Oncolytic Viruses as Immunotherapeutic Agents

Cell death under the influence of OVs occurs under a scenario of immunogenic cell death with a release of danger-associated molecular patterns (DAMPs), which leads to recruitment and activation of dendritic cells and triggering an adaptive T-cell immune response.

Molecular Mechanisms of Anti-Neoplastic and Immune Stimulatory Properties of Oncolytic Newcastle Disease Virus

The present review provides an update of the molecular mechanisms of the anti-neoplastic and immune stimulatory properties of the avian paramyxovirus, Newcastle Disease Virus (NDV), in which the viral hemagglutinin-neuraminidase (HN) protein plays a prominent role.

Cancer Vaccines and Oncolytic Viruses Exert Profoundly Lower Side Effects in Cancer Patients than Other Systemic Therapies: A Comparative Analysis

A clear-cut difference is observed with regard to major adverse events (WHO grades 3–4).

Addition of Multimodal Immunotherapy to Combination Treatment Strategies for Children with DIPG: A Single Institution Experience

Multimodal immunotherapy is feasible as scheduled, until progression, in all patients without major toxicity, and warrants further investigation as part of a combinatorial treatment approach for children diagnosed with DIPG.

References

SHOWING 1-10 OF 51 REFERENCES

Localized Oncolytic Virotherapy Overcomes Systemic Tumor Resistance to Immune Checkpoint Blockade Immunotherapy

Intratumoral treatment with an oncolytic virus results in inflammatory infiltrates in distant tumors and sensitizes the tumors to immune-mediated rejection in the setting of immunotherapy with CTLA-4

Oncolytic Newcastle Disease Virus as Cutting Edge between Tumor and Host

Newcastle Disease Virus (NDV), a bird RNA virus of the paramyxovirus family, appears outstanding and helps to prepare the cancer-bearing host for immunocompetence and instruct the patient’s immune system with information about tumor-associated antigens of its own tumor together with danger signals derived from virus infection.

Oncolytic Newcastle disease virus as a prospective anti-cancer therapy. A biologic agent with potential to break therapy resistance

Of the various combinatorial approaches discussed, the most promising and feasible for clinical practice appears to be the combination of systemic NDV pre-treatment with anti-tumor vaccination.

Autologous tumor cell vaccines for post-operative active-specific immunotherapy of colorectal carcinoma: long-term patient survival and mechanism of function

The observed improvement of long-term survival is explained by activation and mobilization of a pre-existing repertoire of tumor-reactive memory T cells which, according to recent discoveries, reside in distinct niches of patients' bone marrow in neighborhood with hematopoietic and mesenchymal stem cells.

Antitumor Vaccination in Patients with Head and Neck Squamous Cell Carcinomas with Autologous Virus-Modified Tumor Cells

Immune monitoring revealed significant increases of antitumor delayed type hypersensitivity reactivity especially in disease-free patients, and in a significant proportion of vaccinated patients the presence of tumor-reactive T-cells in the peripheral blood even 5 to 7 years after the last vaccination.

Antitumor vaccination of patients with glioblastoma multiforme: a pilot study to assess feasibility, safety, and clinical benefit.

Postoperative vaccination with virus-modified autologous tumor cells seems to be feasible and safe and to improve the prognosis of patients with glioblastomas, substantiated by the observed antitumor immune response.

Dendritic Cells Pulsed with Viral Oncolysate

The use of dendritic cell (DC)-based active vaccination to bolster the otherwise impaired antitumour immune responses in glioma patients has received increasing attention, but results have unfortunately rarely translated into strong clinical effects.

Molecular and Translational Classifications of DAMPs in Immunogenic Cell Death

The main molecular, immunological, preclinical, and clinical aspects of ICD are summarized and tabulate in an attempt to capture the essence of this phenomenon, and identify future challenges for this rapidly expanding field of investigation.

Immunization with virus-modified tumor cells.

An efficient, selective, and safe way of infecting human tumor cells with a natural virus with interesting pleiotropic immune stimulatory properties, the avian paramyxovirus Newcastle disease virus (NDV).

Tumor-cell number and viability as quality and efficacy parameters of autologous virus-modified cancer vaccines in patients with breast or ovarian cancer.

Quality and efficacy criteria of an autologous, physically and immunologically purified, Newcastle disease virus (NDV)-modified, irradiated tumor-cell vaccine (ATV-NDV) are investigated by analyzing three independent cohorts of patients vaccinated between 1991 and 1995 to imply clinical effectivity in breast and ovarian cancer with ATV- NDV high-quality vaccine.
...